These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 2394034)
1. Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase. Spitzer RE; Stitzel AE; Tsokos GC Clin Immunol Immunopathol; 1990 Oct; 57(1):19-31. PubMed ID: 2394034 [TBL] [Abstract][Full Text] [Related]
2. Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event. Spitzer RE; Stitzel AE; Tsokos GC J Pediatr; 1990 May; 116(5):S103-8. PubMed ID: 2329411 [TBL] [Abstract][Full Text] [Related]
3. Autoantibody to the alternative pathway C3/C5 convertase and its anti-idiotypic response. A study in affinity. Spitzer RE; Stitzel AE; Tsokos GC J Immunol; 1992 Jan; 148(1):137-41. PubMed ID: 1727863 [TBL] [Abstract][Full Text] [Related]
4. Study of the idiotypic response to autoantibody to the alternative pathway C3/C5 convertase in normal individuals, patients with membranoproliferative glomerulonephritis, and experimental animals. Spitzer RE; Stitzel AE; Tsokos GC Clin Immunol Immunopathol; 1992 Mar; 62(3):291-4. PubMed ID: 1541054 [TBL] [Abstract][Full Text] [Related]
5. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis. Hiramatsu M; Balow JE; Tsokos GC J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894 [TBL] [Abstract][Full Text] [Related]
6. Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. Spitzer RE; Stitzel AE; Tsokos GC Clin Immunol Immunopathol; 1990 Oct; 57(1):10-8. PubMed ID: 1697516 [TBL] [Abstract][Full Text] [Related]
7. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. Strife CF; Prada AL; Clardy CW; Jackson E; Forristal J J Pediatr; 1990 May; 116(5):S98-102. PubMed ID: 2329415 [TBL] [Abstract][Full Text] [Related]
8. Human polyclonal and monoclonal IgG and IgM complement 3 nephritic factors: evidence for idiotypic commonality. Tsokos GC; Stitzel AE; Patel AD; Hiramatsu M; Balow JE; Spitzer RE Clin Immunol Immunopathol; 1989 Oct; 53(1):113-22. PubMed ID: 2475285 [TBL] [Abstract][Full Text] [Related]
9. Further evidence for the antibody nature of C3 nephritic factor (C3NeF). Daha MR; van Es LA J Immunol; 1979 Aug; 123(2):755-8. PubMed ID: 379217 [TBL] [Abstract][Full Text] [Related]
10. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. Frémeaux-Bacchi V; Weiss L; Brun P; Kazatchkine MD Nephrol Dial Transplant; 1994; 9(7):811-4. PubMed ID: 7970124 [TBL] [Abstract][Full Text] [Related]
11. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M Front Immunol; 2018; 9():2329. PubMed ID: 30487789 [TBL] [Abstract][Full Text] [Related]
12. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF. Tanuma Y; Ohi H; Hatano M Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128 [TBL] [Abstract][Full Text] [Related]
13. On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production. Spitzer RE; Stitzel AE; Tsokos G Clin Immunol Immunopathol; 1992 Sep; 64(3):177-83. PubMed ID: 1386563 [TBL] [Abstract][Full Text] [Related]
14. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor. Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408 [TBL] [Abstract][Full Text] [Related]
15. Anti-factor B autoantibody in dense deposit disease. Strobel S; Zimmering M; Papp K; Prechl J; Józsi M Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965 [TBL] [Abstract][Full Text] [Related]
16. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase. Ng YC; Peters DK Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695 [TBL] [Abstract][Full Text] [Related]
17. Nucleotide sequence of a human autoantibody to the alternative pathway C3/C5 convertase (C3NeF). Victor KD; Pascual V; Stitzel AE; Tsokos GC; Capra JD; Spitzer RE Hybridoma; 1993 Jun; 12(3):231-7. PubMed ID: 8395463 [TBL] [Abstract][Full Text] [Related]
18. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus. Waldo FB; Forristal J; Beischel L; West CD J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752 [TBL] [Abstract][Full Text] [Related]
19. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase. Daha MR; van Es LA J Immunol; 1979 Mar; 122(3):801-5. PubMed ID: 448075 [TBL] [Abstract][Full Text] [Related]
20. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III. West CD; McAdams AJ Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]